

PROGRAM



Bio-Neuroscience

Amsterdam, 24th-26th February, 2026

THE GLOBAL SUMMIT FOR LEADERS
AND DECISION-MAKERS IN
NEUROSCIENCES DRUG
DEVELOPMENT

Key Opinion Leaders
Industry Executives
Startups Founders
C-level Executives
Investors



INSIGHT - ACCESS - ENGAGEMENT - IMPACT

AN INITIATIVE OF



CO-ORGANIZED WITH





14:00

COFFEE & REGISTRATION

14:30

Roundtable Networking - Coffee and a Series of Networking Tables

Participant networking at a series of pre-scheduled roundtables for accelerated introductory networking.

15:00

Pre-Summit Roundtable Discussion - Innovation in BoNT Based Therapies for Neurological and Psychiatric Disorders

Stefan König

CEO - Merz Therapeutics

Eric Finzi

Co-Founder - Healis Therapeutics

Marc Axel Wollmer

Head of department, Department of Old Age Psychiatry - Asklepios Clinic North - Ochsenzoll

Tillmann Krüger

Associate Professor, Deputy Head of Department - Psychiatry, Social Psychiatry and Psychotherapy, Head of Section of Clinical Psychology & Sexual Medicine - Hannover Medical School

15:45

COFFEE BREAK

16:00

Welcome to Bio-Neuroscience: Official Inauguration

Christian J Suojanen

CEO - Broadreach Global

Andrea Soto Padilla

Business Development - Amsterdam Neuroscience, Amsterdam UMC

16:15

The need for Innovation in Pre-Clinical and Para-Clinical Models

José Luís Lanciego

Laboratory of Gene Therapy for Parkinson's Disease - CIMA, University of Navarra, & President - European Brain Foundation

Joshua Bagely

Chief Scientific Officer - ahead bio AG



DAY I

TUESDAY 24 FEB. 2026



Bio-Neuroscience

16:45

Innovation in Biomarkers to accelerate clinical research and improve clinical care

Joachim Reischl

VP & Franchise Head, Neurodegenerative Disease, Center of Innovation - Danaher Diagnostics

Charlotte Teunissen

Professor in Neurochemistry - Amsterdam UMC

17:15

Venture Philanthropy, Charity and Foundation - Financed Neuroscience Drug Development

Giovanna Lalli

Director of Strategy & Operations – LifeArc

Opher Kornfeld

Director, Translational Research and Development - SPARK NS

Lynsey Bilslund

Managing Director of Parkinson's Virtual Biotech - Parkinson's UK

18:00

Welcome Reception Remarks

18:05

WELCOME RECEPTION & NETWORKING



Bio-Neuroscience



Bio-Neuroscience



08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Opening Remarks

Christian J Suojanen

CEO - Broadreach Global

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam
Neuroscience UMC

09:15

The Regulatory Perspective in Neuroscience Drug Development

Moderator: Philip Scheltens, Managing Partner - EQT Dementia Fund, Partner EQT Life Sciences

Pavel Balabanov

Head of Therapies for Neurological and
Psychiatric Disorders - European Medicines
Agency (EMA)

10:00

Therapeutics Development for Rare Neurological Diseases; Financing, Clinical and Regulatory Challenges and the Patient and Startup Perspective

Discussion Panel

Moderator: Yael Weiss, CEO - Mahzi Therapeutics

A discussion with stakeholders in rare pediatric neurological disease innovation; from rare families developing therapies, to KOL collaborators and specialized industry partners.

Stuart Cobb

Chief Scientific Officer - Neurogene Inc, Principal
Investigator - The University of Edinburgh

Andy Stevenson

Clinical Trial Lead - Reverse Rett

10:45

NETWORKING COFFEE BREAK

11:15

The Investment Bank Perspective: Navigating the State of Capital Markets and M&A as it impacts Neuroscience Drug Development

Moderator: Bruce Leuchter, President & CEO - Neurvati Neurosciences

Kevin Sheridan

Joint Global Head of Healthcare Investment
Banking - Jefferies LLC

Eric Stewart

Senior Managing Director, Healthcare Mergers
& Acquisitions - Leerink Partners

Sven Pfeiffer

Partner, Strategic Advisory Group - PJT Partners





12:00

Investor Session – The current Investment Landscape for CNS Neuroscience Drug Development

In light of evolving geopolitical, market, and regulatory conditions - what does it mean for private biotech?

Moderator: Hakan Goker, Managing Director & Head of Life Sciences – M-Ventures

Thomas Michael Thestrup	Senior Principal - Angelini Ventures
Henriette Richter	Managing Partner - Sofinnova Partners
Joao Barbosa da Silva	Investor - re.Mind Capital
Keno Gutierrez	General Partner - BioGeneration Ventures (BGV)

12:45

LUNCH & NETWORKING BREAK - HOSTED BY MERZ THERAPEUTICS



THERAPEUTICS

Better outcomes for more patients.

14:00

Fireside Chat – A Strategic Venture to develop a Disease Modifying Therapy for GBA Parkinson’s Disease

Moderator: Kees Been, CEO, Kynexis Therapeutics

António Portela	CEO - BIAL
-----------------	------------

14:45

Neuroinflammation; tackling indications from MS to PD and AD Key advances, core challenges, and strategies going forward in current market conditions.

Jing Wang	Co-Founder & Chief Executive Officer - Myrobalan Therapeutics
Marcelo Bigal	President & Chief Executive Officer - Ventus Therapeutics
Niels Plath	Chief Scientific Officer – Muna Therapeutics
Christian Mirescu	Chief Scientific Officer – Monument Biosciences

15:30

NETWORKING COFFEE BREAK





16:00

Pricing, Reimbursement, and Survival for Neuroscience Therapeutics
Navigating the policy tightrope, the investor and biotech perspectives, and strategies and innovative models for a new era.

Alexander Natz

Secretary General - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Silvia Chiroli

Head of Pricing & Market Access EMEA - ArgenX

16:45

COMPANY PITCH SESSION

Selected companies present to an industry & investor panel

17:45

END OF DAY II & NETWORKING RECEPTION - HOSTED BY DANAHER





08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Opening Remarks

09:15

Keynote II - Engineering AAVs for human CNS Gene Therapy

Ben Deverman

Director, Vector Engineering at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard

10:00

Gene therapy 2.0 in Neuroscience

The evolution of gene therapies, current approaches, opportunities and challenges from the scientific, clinical, regulatory and market perspectives.

Moderator: Robert Thorne, Denali Fellow – Denali Therapeutics, President - International Brain Barriers Society (IBBS)

Alex Bloom

CTO - AviadoBio

Andrew Steinsapir

Acting CTO - Apertura Gene Therapy, & Director, Gene Therapy Program Lead - Deerfield Management

Marco Weinberg

Senior Vice President, Head of Research, uniQur

Sander van Deventer

President R&D, VectorY Therapeutics

10:45

NETWORKING COFFEE BREAK

11:15

Fireside Chat - Anatomy of a deal; Discussing the Angelini Pharma and GRIN Therapeutics deal, one year in

Moderator: Christian J. Suojanen, CEO – Broadreach Global

Jacopo Andreose

CEO - Angelini Pharma S.p.A.

Bruce Leuchter

President & CEO - Neurvati Neurosciences





12:00

Novel modalities, from Oligonucleotides to RNA Therapeutics in CNS Rare Diseases: Science, Approvals, Approaches and Deals.

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Vikas Sharma

Chief Business Officer - QurAlis

12:45

LUNCH & NETWORKING BREAK

14:00

COMPANY PITCH SESSION

Selected companies present to an industry & investor panel

14:45

Industry Panel - Partnering With Industry

Jenny Laird

VP, Business Development Neuroscience - Eli Lilly

Richard Reschen

Director, Business Development & Licensing - MSD

Christian Thomsen

Global External CNS Research - Boehringer Ingelheim

Karen LaRochelle

Global Head of Business Strategy & Portfolio Innovation - Merz Therapeutics

Marta Helena Lesko

VP, Head of Neurology and Immunology Business Development - Merck Group

15:45

Bio-Neuroscience Awards

Company Pitch Awards


16:00

Closing Remarks

16:15

END OF SUMMIT - NETWORKING RECEPTION





THANK YOU TO OUR SPONSORS

Gold Sponsors



THERAPEUTICS

Better outcomes for more patients.

Founding Sponsors



Bronze Sponsors



Partners



An Initiative of:	Co-Organized with: